Insider Selling: Intellia Therapeutics Inc (NTLA) CEO Sells 336,783 Shares of Stock
Intellia Therapeutics Inc (NASDAQ:NTLA) CEO Nessan Bermingham sold 336,783 shares of Intellia Therapeutics stock in a transaction on Friday, December 8th. The stock was sold at an average price of $20.78, for a total value of $6,998,350.74. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of Intellia Therapeutics Inc (NASDAQ NTLA) traded up $0.08 during trading hours on Friday, hitting $21.22. The company had a trading volume of 614,091 shares, compared to its average volume of 345,697. Intellia Therapeutics Inc has a 1 year low of $10.83 and a 1 year high of $33.34.
Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.06. The firm had revenue of $7.30 million during the quarter, compared to the consensus estimate of $5.83 million. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The company’s quarterly revenue was up 49.0% on a year-over-year basis. During the same period last year, the company earned ($0.22) EPS. analysts predict that Intellia Therapeutics Inc will post -1.68 earnings per share for the current fiscal year.
NTLA has been the topic of several analyst reports. Barclays reiterated a “buy” rating on shares of Intellia Therapeutics in a report on Sunday, November 5th. Jefferies Group set a $42.00 price target on Intellia Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 31st. ValuEngine upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. Zacks Investment Research raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, Chardan Capital downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 price objective for the company. in a research report on Tuesday, August 29th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $30.17.
Several large investors have recently modified their holdings of the stock. GSA Capital Partners LLP increased its position in shares of Intellia Therapeutics by 28.9% during the 3rd quarter. GSA Capital Partners LLP now owns 73,100 shares of the company’s stock worth $1,817,000 after purchasing an additional 16,400 shares during the last quarter. Neuberger Berman Group LLC increased its position in shares of Intellia Therapeutics by 23.0% during the 3rd quarter. Neuberger Berman Group LLC now owns 60,915 shares of the company’s stock worth $1,514,000 after purchasing an additional 11,398 shares during the last quarter. Granahan Investment Management Inc. MA grew its position in Intellia Therapeutics by 7.0% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 286,144 shares of the company’s stock valued at $7,111,000 after acquiring an additional 18,784 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in Intellia Therapeutics by 34.7% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 57,492 shares of the company’s stock valued at $1,429,000 after acquiring an additional 14,818 shares in the last quarter. Finally, GMT Capital Corp acquired a new position in Intellia Therapeutics in the 3rd quarter valued at about $8,214,000. 49.53% of the stock is owned by hedge funds and other institutional investors.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.